152 related articles for article (PubMed ID: 29262547)
1. Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6.
Li YZ; Yu S; Yan PA; Gong DY; Wu FL; He Z; Yuan YY; Zhao AY; Tang X; Zhang RQ; Peng C; Cao ZX
Oncotarget; 2017 Nov; 8(61):103087-103099. PubMed ID: 29262547
[TBL] [Abstract][Full Text] [Related]
2. Rational discovery of dual FLT3/HDAC inhibitors as a potential AML therapy.
Wang Z; Wu D; Zhao X; Liu C; Jia S; He Q; Huang F; Cheng Z; Lu T; Chen Y; Chen Y; Yang P; Lu S
Eur J Med Chem; 2023 Nov; 260():115759. PubMed ID: 37659198
[TBL] [Abstract][Full Text] [Related]
3. The Identification of APOBEC3G as a Potential Prognostic Biomarker in Acute Myeloid Leukemia and a Possible Drug Target for Crotonoside.
Ma C; Liu P; Cui S; Gao C; Tan X; Liu Z; Xu R
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144542
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3.
Wachholz V; Mustafa AM; Zeyn Y; Henninger SJ; Beyer M; Dzulko M; Piée-Staffa A; Brachetti C; Haehnel PS; Sellmer A; Mahboobi S; Kindler T; Brenner W; Nikolova T; Krämer OH
Arch Toxicol; 2022 Jan; 96(1):177-193. PubMed ID: 34665271
[TBL] [Abstract][Full Text] [Related]
5. Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Anti-Acute Myeloid Leukemia Efficacy In Vitro and In Vivo.
Cao ZX; Wen Y; He JL; Huang SZ; Gao F; Guo CJ; Liu QQ; Zheng SW; Gong DY; Li YZ; Zhang RQ; Chen JP; Peng C
Mol Pharmacol; 2019 Nov; 96(5):589-599. PubMed ID: 31462456
[TBL] [Abstract][Full Text] [Related]
6. Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression.
Zhang D; Guo Y; Zhao Y; Yu L; Chang Z; Pei H; Huang J; Chen C; Xue H; Xu X; Pan Y; Li N; Zhu C; Zhao ZJ; Yu J; Chen Y
Microb Cell Fact; 2021 Mar; 20(1):67. PubMed ID: 33691697
[TBL] [Abstract][Full Text] [Related]
7. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
8. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
9. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
10. Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.
Latuske EM; Stamm H; Klokow M; Vohwinkel G; Muschhammer J; Bokemeyer C; Jücker M; Kebenko M; Fiedler W; Wellbrock J
Oncotarget; 2017 Apr; 8(17):29187-29201. PubMed ID: 28418873
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia.
Gu S; Hou Y; Dovat K; Dovat S; Song C; Ge Z
Exp Hematol Oncol; 2023 Feb; 12(1):23. PubMed ID: 36849955
[TBL] [Abstract][Full Text] [Related]
12. A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia.
Czardybon W; Windak R; Gołas A; Gałęzowski M; Sabiniarz A; Dolata I; Salwińska M; Guzik P; Zawadzka M; Gabor-Worwa E; Winnik B; Żurawska M; Kolasińska E; Wincza E; Bugaj M; Danielewicz M; Majewska E; Mazan M; Dubin G; Noyszewska-Kania M; Jabłońska E; Szydłowski M; Sewastianik T; Puła B; Szumera-Ciećkiewicz A; Prochorec-Sobieszek M; Mądro E; Lech-Marańda E; Warzocha K; Tamburini J; Juszczyński P; Brzózka K
Oncotarget; 2018 Mar; 9(24):16917-16931. PubMed ID: 29682194
[TBL] [Abstract][Full Text] [Related]
13. FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia.
Fang DD; Zhu H; Tang Q; Wang G; Min P; Wang Q; Li N; Yang D; Zhai Y
Transl Oncol; 2022 Jan; 15(1):101244. PubMed ID: 34710737
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.
Lin WH; Yeh TK; Jiaang WT; Yen KJ; Chen CH; Huang CT; Yen SC; Hsieh SY; Chou LH; Chen CP; Chiu CH; Kao LC; Chao YS; Chen CT; Hsu JT
PLoS One; 2014; 9(1):e83160. PubMed ID: 24416160
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
[TBL] [Abstract][Full Text] [Related]
16. Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach.
Yen SC; Chen LC; Huang HL; HuangFu WC; Chen YY; Eight Lin T; Lien ST; Tseng HJ; Sung TY; Hsieh JH; Huang WJ; Pan SL; Hsu KC
Bioorg Chem; 2022 Apr; 121():105675. PubMed ID: 35182882
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
[TBL] [Abstract][Full Text] [Related]
18. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X
BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
[TBL] [Abstract][Full Text] [Related]
20. Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.
Zhang W; Yu G; Zhang H; Basyal M; Ly C; Yuan B; Ruvolo V; Piya S; Bhattacharya S; Zhang Q; Borthakur G; Battula V; Konopleva M; Rice WG; Andreeff M
Haematologica; 2023 Jun; 108(6):1500-1514. PubMed ID: 36226489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
